Business Wire05.07.19
LabConnect, a global provider of central laboratory and support services for biopharmaceutical, pharmaceutical, medical device, and contract research organizations, has appointed Dr. Anthony Todd Everhart to serve as medical director. At LabConnect, Dr. Everhart’s primary duties will be to serve as medical liaison to central laboratory medical directors, expanding the use of visual analytics, and advising Data Management and Scientific Affairs on data integration, data normalization, and data harmonization. He will contribute a wealth of industry skills and experience to LabConnect and his appointment will bring yet another level of valuable expertise for the clients of LabConnect’s premium central lab services.
According to LabConnect Chairman Eric Richman, “Dr. Everhart's expertise is medical monitoring and clinical data review for complex studies with experience in management of over 30 clinical trials. In this era of ever-increasing data, his focus has been on medical data review using visual analytics to ensure and optimize data quality. We welcome his expertise in technology adoption and in developing methodologies and tools for technology implementation.”
Dr. Everhart is an innovator, educator, and leader in the pharmaceutical and biotechnology industries, bringing over 11 years of experience in complex clinical development to LabConnect. Prior to joining, he served as vice president of medical informatics at Chiltern/Covance, vice president of medical affairs Americas at Chiltern, and medical director at Clinical Trial Management Services (CTMS). Board-certified in internal medicine and a fellow of the American College of Physicians, he has worked in all phases of clinical development in numerous therapeutic areas including allergy and immunology, cardiovascular, hematology and oncology, infectious disease and HIV, neurology, ophthalmology, psychiatry, respiratory, and rheumatology.
Founded in 2002, LabConnect provides global central laboratory and client-inspired support services including routine and specialized laboratory testing, kit building, sample management and tracking, data management, biorepository and scientific support services for biopharmaceutical and CRO clients. LabConnect’s unique combination of state-of-the-art technology, laboratories, easy access to major and emerging markets and extensive specialized testing expertise means that drug development companies can rely on one provider for their central laboratory and preclinical through Phase IV clinical development needs.
According to LabConnect Chairman Eric Richman, “Dr. Everhart's expertise is medical monitoring and clinical data review for complex studies with experience in management of over 30 clinical trials. In this era of ever-increasing data, his focus has been on medical data review using visual analytics to ensure and optimize data quality. We welcome his expertise in technology adoption and in developing methodologies and tools for technology implementation.”
Dr. Everhart is an innovator, educator, and leader in the pharmaceutical and biotechnology industries, bringing over 11 years of experience in complex clinical development to LabConnect. Prior to joining, he served as vice president of medical informatics at Chiltern/Covance, vice president of medical affairs Americas at Chiltern, and medical director at Clinical Trial Management Services (CTMS). Board-certified in internal medicine and a fellow of the American College of Physicians, he has worked in all phases of clinical development in numerous therapeutic areas including allergy and immunology, cardiovascular, hematology and oncology, infectious disease and HIV, neurology, ophthalmology, psychiatry, respiratory, and rheumatology.
Founded in 2002, LabConnect provides global central laboratory and client-inspired support services including routine and specialized laboratory testing, kit building, sample management and tracking, data management, biorepository and scientific support services for biopharmaceutical and CRO clients. LabConnect’s unique combination of state-of-the-art technology, laboratories, easy access to major and emerging markets and extensive specialized testing expertise means that drug development companies can rely on one provider for their central laboratory and preclinical through Phase IV clinical development needs.
